GPR52 Antibody (582671) [DyLight 550]
Novus Biologicals, part of Bio-Techne | Catalog # FAB10357L
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Monoclonal Mouse IgG2A Clone # 582671
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 mouse myeloma cell line transfected with human GPR52
Met1-Ile361
Accession # Q9Y2T5
Met1-Ile361
Accession # Q9Y2T5
Specificity
Detects human GPR52 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for GPR52 Antibody (582671) [DyLight 550]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: GPR52
Long Name
G-Protein-Coupled Receptor 52
Alternate Names
G protein-coupled receptor 52, MGC111751, probable G-protein coupled receptor 52
Additional GPR52 Products
Product Documents for GPR52 Antibody (582671) [DyLight 550]
Product Specific Notices for GPR52 Antibody (582671) [DyLight 550]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...